Tafero-EM (Tenofovir Alafenamide & Emtricitabine)

Tenofovir Alafenamide & Emtricitabine
Contact us for more information
Цвет:
Вариант:
Wishlist Compare
Hetero Drugs Ltd

Tafero-EM (Tenofovir Alafenamide & Emtricitabine)

ManufacturerHetero Drugs LtdBrand nameTafero-EMActive substanceTenofovir Alafenamide & EmtricitabineStrength25mg + 200mgCategoryHIVManufacturerHetero Healthcare Ltd

Description  of  Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg)

 

Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg) is a anti-retroviral medication containing two eminent ingredients known as; Tenofovir Alafenamide fumarate Emtricitabine Tenofovir Alafenamide is a nucleotide reverse transcriptase inhibitor Emtricitabine is a nucleoside reverse transcriptase inhibitor. Both are most effective & potent compounds against HIV-1 infections, but it does not cure the infection condition it is only used for preventing & suppressing the progression of HIV-1 infection into AIDS. In Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg) tablets, TAF is present as a prodrug form. Emtricitabine is synthetic fluoro derivative of thiacytidine.

INDICATIONS of  Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg)

Tafero EM, a combination tablet contains tenofovir Alafenamide fumarate and Emtricitabine is mainly indicated for the treatment of HIV-1 infection in adult’s patients.

MECHANISM OF ACTION  of  Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg)

Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg) contains Tenofovir Alafenamide fumarate and Emtricitabine TAF is pharmacologically nucleotide simple of invert transcriptase inhibitors, which is available as prodrug shape. It gets changed over as a functioning structure in-vivo, known as tenofovir. Tenofovir experiences diminishing the building squares of typical DNA happens. The water atom is basic for the phosphodiester bond linkage. Tenofovir is battling with typical nucleotides for addition into proviral DNA and interference of generation of 5' to 3' phosphodiester linkage which is essential for DNA prolongation. Tenofovir engaged with; Chain disposal DNA stretching end Stops the proviral DNA interpretation Emtricitabine; Emtricitabine is in charge of deterring the viral reverse transcriptase chemical which is essential for viral creation. Emtricitabine includes; Chain disposal Stops the HIV RNA duplicates augmentation Serves to emulates the viral load

 SIDE EFFECTS  of  Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg)

Lactic acidosis, Hepatic steatosis, Serious exacerbation of hepatitis B, Immune reconstitution syndrome, New outbreak or aggravation of renal impairment.
Some side effects are :
Increased cholesterol levels, Serum creatinine level get increased, Bone mineral density effects, CD+ cells counts varies.

PRECAUTION  of  Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg)

Aggravation of hepatitis B infection: Patients should be examine earlier for occurrence of hepatitis B infection or not. The effectiveness of Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg) tablets for advanced hepatitis B infection has not been evaluated. This condition mostly occurred in patients who are HIV-1/HBV co infected. Immune reconstitution syndrome: To overcome the problem by discontinuing the treatment with Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg). Renal impairment worsening: Stop using Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg) with drugs affecting the renal functions. Monitor the creatinine clearance value frequently. In severe conditions CrCl below 30ml/min use of Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg) should be avoid. Lactic acidosis & hepatic steatosis: Discontinue the therapy using Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg)

DRUG INTERACTION  of  Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg)

Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg) + P-gp or BCRP potent inhibitors: affect the absorption of TAF. Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg) + potent P-gp or BCRP inducers: reduce the absorption of TAF causes reducing=g the plasma concentration of TAF and finally results as loss of effectiveness of Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg)Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg) elimination process occurs through kidneys, combination of Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg) with drugs affecting the renal activity causes increasing the effect of concentration of ingredients of Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg) & concludes as elevation of adverse effects associated to these components. Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg) combines with drugs like tipranavir/ritonavir causes diminishing the effect of concentration of TAF. Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg) concurrently used with anti-convulsants causes decreasing the effect of concentration of TAF. Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg) concurrently used with anti-mycobacterials or st Johns wort causes decreasing the effect of concentration of TAF.

CONTRAINDICATION of  Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg)

Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg) is contraindicated to patients with CrCl below 30ml/min Anaphylactic reactions are produced due to patients are contraindicated to the components of Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg).

OVERDOSAGE  of  Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg)

The over dosage of Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg) should be treated with hemodialysis. Emtricitabine should be removed by 30% range after completing 3 hours of dialysis process. TAF should be eliminated by 54% of range after 4 hours dialysis session.

PREGNANCY   of Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg)

Pregnancy category B

Usage of Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg) in pregnancy period is only occurs by knowing the risk benefits associated to Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg).

PEDIATRIC of Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg)

The potency & effectiveness of Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg) should not be evaluated in pediatric patients with weighing below 25kg.

GERIATRIC of Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg)

 

The potency of Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg) should not be evaluated in clinical trials for geriatric patients with age of above 65 years.

RENAL DAMAGE of Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg)

 

The uses of Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg) should be avoided in patients with CrCl below 30ml/min.

DOSAGE of  Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg)

 

The prescribed dose of Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg) is one table should be given orally as once a day. Important points; Before starting the treatment, patient should be examining for presence of hepatitis B infection or not. Patient’s renal values should be investigated like creatinine clearance, urine glucose & urine protein. Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg) should be used in adolescents, pediatric patient with weighing at least 25kg & creatinine clearance of patients should be larger or equal to 30ml/min. Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg) should not be applicable for patients with creatinine clearance below 30ml/min. Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg) tablets should be administered with food or without food.


STORAGE  of  Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg)

 

The storage of Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg) should be kept at temperature below 30℃

Protect the container from moisture, heat & light.

MISSED DOSE of  Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg)

Tafero-EM (Tenofovir Alafenamide 25mg & Emtricitabine 200mg) is an anti-retroviral medicine, On condition of missed dose, the patient should be consult with medical practitioner and maintain the guidance Or skip missed dose and Maintain the regular dosing schedule

Brand name:
Tafero-EM
Active substance:
Tenofovir Alafenamide & Emtricitabine
Strength:
25mg + 200mg
Category:
HIV
Manufacturer:
Hetero Healthcare Ltd
Packaging:
30 Tablet
Product form:
Tablet

No reviews found

Write feedback
Worldwide delivery

Our company ships from India to all countries of the world.

Genuine and Authentic products

All products supplied from the manufacturer of WHO : GMP certified facilities and ISO Certified facilitates

Economical and Affordable prices

All the products are supplying from manufacturing companies of India